BUHLMANN News - Buhlmann Diagnostics Corp - Newsletter - Tradeshow

BUHLMANN News

Visit BUHLMANN at ASCP 2022 (Live)

Assays Offerings BUHLMANN Diagnostic Corp, offers the broadest fecal calprotectin (fCAL) product range in the industry. These include FDA cleared ...
Read More

Visit BUHLMANN at AACC 2022 (Live)

Assays Offerings Assays Offerings: BUHLMANN Diagnostic Corp (BDC), offers the broadest fecal calprotectin (fCAL) product range in the industry, available ...
Read More

Visit BUHLMANN at DDW 2022

Assays Offerings Assays Offerings: We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United ...
Read More

Buhlmann – Next Generation Food Allergy Drug Development Summit

Next Generation Food Allergy Drug Development Summit, July 20-22, 2021: BUHLMANN is proud to partner with this event, specifically focused ...
Read More

Digestive Disease Week 2021

Assays Offerings We offer the broadest fecal calprotectin (fCAL) product range in the industry, available in the United States, including ...
Read More

Visit BUHLMANN at AACC 2021 (LIVE)

Assays Offerings Assays Offerings: BUHLMANN Diagnostic Corp (BDC), offers the broadest fecal calprotectin (fCAL) product range in the industry, available ...
Read More

BUHLMANN Diagnostic Corp – New Partner Channel Agreement with Roche Diagnostics

Announcement BUHLMANN Diagnostic Corp is pleased to announce a new partner channel agreement with Roche Diagnostics for the launch and ...
Read More

Educational Webinar recording from AMLI presentation by Dr Arne Roseth

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 Abstract Inflammatory Bowel Disease (IBD) is a ...
Read More